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3`	UTR	 	 	 3`	untranslated	region	
AGO	 	 	 Argonaute		
AKT1	 	 	 Thymoma	viral	proto-oncogene	1	
Apoe	 	 	 Apolipoprotein	e	
ATP	 	 	 Adenosine	triphosphate	
BCL6	 	 	 B-cell	lymphoma	6	
C.	elegans	 	 Caenorhabditis	elegans	
CCL2	 	 	 C-C	motif	chemokine	2	
CVD	 	 	 Cardiovascular	disease	
CX3CL1	 	 	 C-X3-C	motif	chemokine	1	
CXCL1	 	 	 C-X-C	motif	chemokine	1	
DGCR8	 	 	 DiGeorge	syndrome	critical	region	8	protein		
dsRNA	 	 	 Double-stranded	RNA	
EC	 	 	 Endothelial	cell	
ER	 	 	 Endoplasmatic	reticulum		
GTP	 	 	 Guanosine	triphosphate	
HAEC	 	 	 Human	aortic	endothelial	cell	
HIF-1α	 	 	 Hypoxia-inducible	factor-1α		
HuR	 	 	 ELAV-like	protein	1	
IPOA3	 	 	 Importin	α3	
KLF2	 	 	 Krüppel-like	factor	2	
KLF4	 	 	 Krüppel-like	factor	4	
LDL	 	 	 Low-density	lipoprotein	
LPA	 	 	 Lysophosphatidic	acid		
miR	 	 	 MicroRNA	
miRNA	 	 	 MicroRNA	
miRNA*	 	 Passenger	microRNA	
moxLDL	 	 Mildly-oxidized	low-density	lipoprotein	
mRNA	 	 	 Messenger	RNA		
NF-κB	 	 	 Nuclear	factor-κB	
NO	 	 	 Nitric	oxide	
NOS2	 	 	 Nitric	oxide	synthase	2		
NOS3	 	 	 Nitric	oxide	synthase	3	
oxLDL	 	 	 Oxidized	low-density	lipoprotein	




R&D	 	 	 Research	and	development	
RISC	 	 	 RNA-induced	silencing	complex	
SHIP-1	 	 	 Src	homology	2	domain-containing	inositol-5-phosphatase	




SOCS1	 	 	 Suppressor	of	cytokine	signaling	1	
TAK1	 	 	 Transforming	growth	factor	β-activated	kinase	1	
TLR4	 	 	 Toll-like	receptor	4		
TNF-α	 	 	 Tumor-necrosis	factor-α	
TSB	 	 	 Target	site	blocker	oligonucleotides	
VEGF	 	 	 Vascular	endothelial	growth	factor	
XPO5	 	 	 Exportin	5	
YY1	 	 	 Yin	Yang	1	











































Cardiovascular	diseases	 (CVDs)	are	 responsible	 for	30	%	of	all	deaths	worldwide,	being	 the	 leading	
cause	of	death	and	loss	of	productive	life	years	among	Europeans	and	around	the	world1,2.	Although	
novel	treatments	of	CVDs	in	the	past	30	years	increased	life	expectancy	by	almost	4	years,	more	than	
4	 million	 Europeans	 still	 die	 from	 CVDs	 per	 year,	 mainly	 due	 to	 coronary	 heart	 disease	 or	
cerebrovascular	disease3,4.	The	incidence	of	CVDs	in	Europe	is	rising	due	to	an	increased	prevalence	








Atherosclerosis,	 the	 main	 cause	 of	 CVDs,	 is	 a	 chronic	 inflammatory	 disease	 of	 blood	 vessels	
characterized	by	the	formation	of	 lesions	due	to	the	accumulation	of	 lipids,	 inflammatory	cells	and	
extracellular	 matrix	 in	 the	 subendothelial	 space	 of	 arteries7.	 Atherosclerotic	 lesions	 have	 been	
histologically	classified	into	six	major	types,	representing	the	early,	developing	and	advanced	stage	of	
atherosclerosis	 (Figure	 1)8.	 The	 initiation	 of	 atherosclerosis	 is	 mediated	 by	 the	 recruitment	 of	
circulating	monocytes	to	inflammatory	activated	endothelial	cells	(ECs)	that	predominantly	occurs	at	
arterial	branching	points,	where	blood	flow	is	naturally	disturbed9.	Monocytes	transmigrate	into	the	
intima	 of	 arteries,	 where	 they	 differentiate	 into	 macrophages	 for	 phagocytic	 clearance	 of	
cholesterol-rich	lipoproteins10.	Increased	intracellular	accumulation	of	lipids	transforms	macrophages	
into	foam	cells,	which	 leads	to	 intimal	thickening	and	to	the	formation	of	fatty	streaks7.	Over	time,	
this	process	 continues	 and	multiple	 foam	cell	 layers	 are	 formed8.	 In	 addition,	 impaired	 lipoprotein	
clearance	induces	extracellular	lipid	deposition,	thereby	developing	fatty	streaks	into	preatheromas7.	
Intimal	 thickening,	 fatty	 streaks,	 and	 preatheromas	 are	 physiological	 stages	 that	 remain	 clinically	
silent	 and	 are	 potentially	 reversible8.	 These	 early	 atherosclerotic	 lesions	 are	 detectable	 in	 every	
human,	 including	 children	 and	 in	 various	 free-living	 animals,	 such	 as	 elephants	 or	 birds7,11-13.	 The	
progression	 of	 atherosclerosis	 and	 the	 formation	 of	 pathological	 lesions	 is	 driven	 by	 the	
inflammatory	 activation	 of	 lipid-laden	 macrophages	 due	 to	 ongoing	 lipid	 accumulation,	 which	
triggers	 macrophage	 apoptosis10.	 Impaired	 phagocytosis	 of	 apoptotic	 cells	 contributes	 to	 the	
formation	 of	 a	 highly	 thrombogenic,	 lipid-rich	 necrotic	 core	 in	 the	 lesions,	 which	 is	 a	 hallmark	 of	
atheromas10.	 These	 vulnerable	 plaques	 are	 prone	 for	 rupture	 and	 thrombosis.	 A	 fibrous	 cap	
consisting	 of	 smooth	muscle	 cells	 (SMCs)	 and	 collagen	 fibrils	 can	 cover	 the	 lipid	 core	 in	 advanced	
lesions,	 which	 may	 provide	 plaque	 stability	 and	 protect	 from	 plaque	 rupture14,15.	 Over	 time,	
complicated	 lesions	 with	 thin	 fibrous	 caps	 can	 develop,	 which	 can	 narrow	 the	 arterial	 lumen,	














ECs	 form	 a	 thin	 monolayer	 at	 the	 luminal	 side	 of	 blood	 or	 lymphatic	 vessels	 and	 regulate	 many	
physiological	processes,	including	vascular	tone,	permeability	and	maintenance	of	blood	fluidity16.	In	
contrast	 to	 veins,	 arterial	 ECs	 are	 exposed	 to	 hemodynamic	 forces	 characterized	 by	 high-pressure	
and	high-shear	stress,	which	is	generated	by	laminar	blood	flow	(Figure	2)17.	ECs	sense	and	convert	
hemodynamic	 forces	 by	 mechanotransduction	 of	 high-shear	 stress	 into	 cellular	 signaling,	 such	 as	
activation	of	the	transcription	factors	Krüppel-like	factor	(KLF)	2	and	4,	which	provide	a	quiescent	EC	
phenotype	 characterized	by	 low	 turnover	 rates,	 tight	 intercellular	 junctions	with	 low	permeability,	
anti-inflammatory	 and	 anti-thrombogenic	 properties18-20.	 Therefore,	 arterial	 ECs	 are	 perfectly	
adapted	to	the	mechanical	stress,	which	promotes	EC	quiescence.	However,	 the	circulatory	system	
requires	 branching	 of	 the	 arteries	 to	 conduct	 blood	 flow	 throughout	 the	 body,	 which	 causes	
permanent	 disturbed	 flow	 and	 low	 shear	 stress17.	 Disturbed	 blood	 flow	 induces	 chronic	 EC	 injury,	
characterized	 by	 the	 upregulation	 of	 adhesion	molecules	 and	 increased	 EC	 apoptosis,	 indicating	 a	
maladaption	of	ECs	to	flow	conditions	at	arterial	branching	points	(Figure	2)21,22.	Chronic	EC	injury	at	
bifurcations	 is	 a	 physiological	 event,	 which	 might	 trigger	 the	 formation	 of	 early	 and	 reversible	
atherosclerotic	lesions	even	under	normal	lipid	levels10.		
Additional	 EC	 damage	 by	 hyperlipidemia	 induces	 endothelial	 inflammation	 at	 sites	 of	 disturbed	
flow	 owing	 to	 the	 suppression	 of	 KLF4,	 which	 promotes	 the	 activation	 of	 the	 proinflammatory	
transcription	factor	nuclear	factor-κB	(NF-κB)	due	to	their	mutual	regulation	via	competitive	binding	
to	 the	 coactivator	 p300	 (Figure	 2)18,21,23.	 Endothelial	 NF-κB	 activation	 promotes	 atherosclerosis	 in	









Activation	 of	 endothelial	 NF-κB	 triggers	 the	 expression	 and	 secretion	 of	 endothelial	 chemokines	
such	 as	 C-X-C	 motif	 chemokine	 1	 (CXCL1)	 and C-C	 motif	 chemokine	 2	 (CCL2)25,29,30.	 CXCL1	 is	
immobilized	 on	 the	 EC	 surface	 and	 triggers	 monocyte	 adhesion	 by	 activating	 integrins	 on	 the	
monocyte	 surface	 (Figure	 2),	 whereas	 CCL2	 promotes	 the	monocytosis	 during	 hyperlipidemia	 and	
contributes	 to	 the	 transmigration	 of	 adherent	 monocytes	 into	 the	 subendothelial	 space29,31-34.	
Disturbed	 flow	 enhances	 EC	 apoptosis,	 which	 increases	 the	 permeability	 of	 the	 endothelium	 and	
promotes	the	influx	of	lipoproteins,	such	as	the	cholesterol-rich	low-density	lipoprotein	(LDL)	into	the	
vessel	 wall	 during	 hyperlipidemia	 (Figure	 2)35-37.	 Lipoproteins	 are	 retained	 in	 the	 subendothelial	
space	by	binding	 to	proteoglycans,	 thereby	accumulating	 in	 the	 intima38.	Retained	 lipoproteins	can	
undergo	 oxidative	modification	 to	 different	 degrees	 by	 oxidation	 of	 proteins	 and	 polyunsaturated	
fatty	acids	mediated	by	ECs,	SMCs	or	macrophages39.	Compared	to	extensively	oxidized	LDL	(oxLDL),	
mildly-oxidized	LDL	(moxLDL)	is	still	recognized	by	the	LDL	receptor,	but	induces	inflammation	in	ECs	
and	 in	 macrophages	 by	 releasing	 active	 phospholipids40.	 The	 generation	 of	 lysophosphatidic	 acid	
(LPA)	 during	 mild	 oxidation	 of	 LDL	 further	 promotes	 the	 recruitment	 of	 monocytes	 to	 the	
endothelium	 through	 the	 release	 of	 endothelial	 CXCL129.	 Concurrently,	 increased	 accumulation	 of	
lipoproteins	enhances	endothelial	apoptosis,	thereby	perpetuating	the	influx	of	lipoproteins	into	the	
vessel	 wall,	 concomitant	 with	 the	 subsequent	 recruitment	 of	 monocytes	 to	 the	 inflammatory	
endothelium41.		
	
Figure	 2:	 Atherosclerotic	 lesion	 formation	 at	
arterial	 bifurcations.	 Atherosclerosis	
preferentially	 develops	 at	 arterial	 branching	
points,	 where	 blood	 flow	 is	 disturbed.	
Hyperlipidemia	 induces	 endothelial	
inflammation	 at	 sites	 of	 disturbed	 flow	 due	 to	
the	suppression	of	KLF2/4	and	activation	of	NF-
κB.	 Induced	 NF-κB	 activation	 promotes	 the	
expression	 and	 release	 of	 CXCL1	 from	
intracellular	 storage	 of	 ECs,	 which	 immobilizes	
on	the	EC	surface.	CXCL1	mediates	the	adhesion	
of	 monocytes	 to	 the	 endothelium,	 which	
transmigrate	 into	 the	 vessel	 wall	 and	
differentiate	 into	 macrophages.	 Disturbed	 flow	
increases	 EC	 apoptosis,	 which	 triggers	 an	
increased	 influx	 of	 LDL	 into	 the	 subendothelial	
space	due	to	an	increased	permeability	of	the	EC	
monolayer.	 In	 the	 intima,	 LDL	 undergoes	
oxidative	modification.	Macrophages	 ingest	 the	
oxidative	 modified	 LDL	 in	 an	 unrestricted	
manner,	 thereby	 developing	 into	 lipid-laden	
foam	 cells	 and	 promoting	 lesion	 progression10.	
Abbreviations:	CXCL1,	C-X-C	motif	chemokine	1;	
EC,	endothelial	cell;	KLF42/4,	Krüppel-like	factor	







Intimal	 macrophages	 recognize	 and	 ingest	 the	 retained	 lipoproteins	 for	 clearance	 from	 the	
extracellular	 space	 (Figure	2).	OxLDL	 is	no	 longer	able	 to	efficiently	 interact	with	 the	LDL	 receptor,	




cholesterol	 and	 fatty	 acids	 and	 subsequent	 accumulation	 in	 cytosolic	 lipid	 droplets	 as	 cholesteryl	
esters	and	triglycerides,	respectively43.	Due	to	intracellular	lipid	accumulation,	macrophages	become	
lipid-laden	foam	cells43.	Excessive	free	cholesterol	can	be	removed	from	macrophages	to	the	liver	via	
high-density	 lipoproteins	 (HDLs)	 or	 lipid-free	 apolipoproteins	 (such	 as	 apoA-I),	 a	 process	 termed	
cholesterol	 efflux43.	 However,	 continuous	 influx	 of	 lipoproteins	 during	 the	 progression	 of	
atherosclerosis	 overwhelms	 the	 cholesterol	 efflux	 capacity	 of	 macrophages,	 causing	 the	
accumulation	 of	 free	 cholesterol	 in	 the	 endoplasmatic	 reticulum	 (ER)	 and	 plasma	 membrane	 of	
macrophages,	 which	 induces	 ER	 stress	 and	 activation	 of	 the	 proinflammatory	 Toll-like	 receptor	 4	
(TLR4)44-46.	 This	 process	 induces	 macrophage	 apoptosis	 and	 the	 inflammatory	 activation	 of	
macrophages,	which	is	characterized	by	the	upregulation	of	proinflammatory	mediators	such	as	nitric	
oxide	 synthase	 2	 (NOS2)	 and	 CCL247-49.	 The	 proatherogenic	 effect	 of	 NOS2	 is	 characterized	 by	 the	
generation	 of	 the	 oxidant	 species,	 such	 as	 peroxynitrite,	which	 strongly	 promotes	 LDL	 oxidation50.	
The	inflammatory	activation	of	macrophages	persistently	induces	monocyte	recruitment,	lipoprotein	
oxidation	and	impairs	cholesterol	efflux,	thus	promoting	the	ongoing	inflammatory	process51-53.	The	
failure	 to	 resolve	 this	 chronic	 inflammation	 results	 in	 the	 progression	 of	 atherosclerotic	 lesions.	
Efficient	 clearance	 of	 apoptotic	 macrophages	 by	 efferocytosis	 at	 an	 early	 stage	 of	 atherosclerosis	
limits	lesion	formation,	whereas	in	advanced	lesions	impaired	phagocytic	clearance	of	apoptotic	cells	
results	in	secondary	necrosis53.	This	process	contributes	to	the	formation	of	a	lipid-rich	necrotic	core,	
which	consists	of	cholesterol	crystals	and	extracellular	 lipids	and	contributes	 to	 the	vulnerability	of	
advanced	atherosclerotic	 lesions53.	During	 lesion	progression,	 SMCs	migrate	 into	 the	 intima,	which	
encapsulate	and	 stabilize	 the	highly	 thrombogenic	necrotic	 core	by	building	a	 fibrous	cap	 together	





In	1993,	Ambros	et	al.	 discovered	a	 small	non-coding	RNA	 located	 in	 the	 lin-4	 gene	 in	nematodes,	
which	controls	the	development	of	Caenorhabditis	elegans	(C.	elegans)	by	inhibiting	the	translation	













within	 intronic	 regions	 of	 protein-coding	 genes	 or	 non-coding	 genes60,61.	 MiRNA	 genes	 can	 be	
transcribed	 together	 with	 their	 host	 genes,	 like	 miR-103,	 which	 expression	 is	 regulated	 by	 the	
promoter	 of	 its	 host	 gene	 pantothenate	 kinase62.	 Alternatively,	 miRNAs	 can	 reside	 in	 exonic	 or	
intergenic	 regions	 and	 are	 expressed	 by	 their	 own	 promoters60.	 The	 majority	 of	 miRNA	 genes	 is	
transcribed	by	the	RNA	Poylmerase	II	into	a	primary	miRNA	transcript	(pri-miRNA)	with	a	poly(A)-tail	
and	5`cap	(Figure	3)59.	A	typical	pri-miRNA	transcript	contains	approximately	thousand	bases	and	is	
folded	 into	 a	 double-stranded	 hairpin	 structure	 composed	 of	 a	 hairpin	 stem	 (33-35	 base	 pairs),	 a	
terminal	 loop	 and	 two	 single-stranded	 flanking	 segments59.	 The	 mature	 miRNA	 sequence	 is	
embedded	in	the	stem	of	this	hairpin	structure59.	Approximately	50	%	of	miRNA	genes	are	located	as	
clusters	 in	 introns	or	 intergenic	 regions,	which	 are	usually	 co-transcribed	as	one	 long	polycistronic	
transcript63.	During	 transcription	and	before	 splicing,	pri-miRNAs	undergo	 the	 first	maturation	step	



















loop	of	 the	pre-miRNA	 through	 its	helicase	domain,	 and	 the	3`	 and	5`	 end	of	 the	double-stranded	
RNA	 (dsRNA)	by	 its	PAZ	and	Platform	domain,	 respectively70.	 The	3`	pocket	binds	 the	2	nucleotide	
3`	overhang	 structure,	 whereas	 the	 5`	 pockets	 anchors	 the	 5`-phosphorylated	 end	 of	 the	 pre-





5`-phosphorylated	 end	 of	 the	 dsRNA	 terminus	 (molecular	 ruler	 function	 of	 Dicer)	 (Figure	 4)70,71.	
According	to	the	3`	counting	rule,	Dicer	typically	cleaves	the	pre-miRNAs	21–25	nucleotides	from	the	
3`	 overhang	 of	 the	 dsRNA	 terminus59.	Moreover,	 Dicer	 can	 use	 the	 5`	 end	 of	 the	 pre-miRNA	 as	 a	
reference	point	to	locate	the	cleavage	site	~22	nucleotides	from	the	5`	end	of	the	dsRNA	(5`	counting	
rule)70.	 The	5`	 counting	mechanism	 requires	 a	phosphate	 group	 to	efficiently	 recognize	 the	5`	 end	
and	occurs	mainly	when	 the	pre-miRNA	end	 is	 thermodynamically	 unstable70.	 In	 either	 case,	Dicer	
generates	 a	 double-stranded	 miRNA	 duplex	 with	 a	 length	 of	 approximately	 22	 nucleotides	
(Figure	5)68.	In	humans,	Dicer	associates	with	two	dsRNA-binding	proteins	TAR	RNA-binding	protein	2	






a	 head,	 body	 and	 base	 region.	 The	 PAZ	 and	




and	 RNase	 III	 domains	 aligns	 the	 stem	 of	 the	
pre-miRNA	 along	 the	 axis	 of	 the	 protein	 and	
functions	as	a	ruler	by	precisely	positioning	the	
pre-miRNA	 over	 the	 catalytic	 centers	 for	
cleavage.	 Thereby,	 the	 catalytic	 domains	
RNase	 IIIa	 and	 IIIb	 cleave	 approximately	 22	
nucleotides	 in	 distance	 of	 the	 dsRNA	 ends	 of	
the	 pre-miRNA.	 Arrows	 indicate	 the	 cleavage	
sites	 of	 the	 RNase	 IIIa	 and	 IIIb	 domains.	 The	
helicase	domain	in	the	base	forms	a	clamp-like	




Following	 Dicer-mediated	 cleavage,	 the	 miRNA	 duplex	 is	 loaded	 onto	 AGO	 proteins	 in	 an	 ATP-
dependent	manner,	 thereby	 generating	 the	 precursor	 RNA-induced	 silencing	 complex	 (pre-RISC)74.	
During	duplex	unwinding,	the	two	strands	of	the	miRNA	duplex	are	separated	and	the	guide	strand	
remains	bound	to	 the	AGO	protein,	which	 results	 in	 the	 formation	of	 the	mature	RISC	 (Figure	5)68.	




Binding	 to	 AGO	 proteins	 stabilizes	 miRNAs	 by	 protecting	 against	 exonucleolytic	 degradation75.	
Whereas	a	subset	of	miRNAs	is	highly	stable,	the	expression	of	some	miRNAs	is	strongly	dependent	
on	 continuous	 biogenesis	 due	 to	 their	 fast	 turnover	 rates76,77.	 In	 quiescent	 cells,	 the	 majority	 of	







elements,	 which	 are	 predominantly	 located	 in	 the	 3`	 untranslated	 region	 (3`	 UTR)	 of	 the	 target	
mRNA81.	Targeting	of	the	mRNA	in	the	RISC	leads	to	the	recruitment	of	deadenylation	factors,	which	
remove	the	poly(A)-tail	of	the	target	mRNA	and	thus	promote	mRNA	degradation	by	exonucleases68.	
In	addition,	 the	miRNA-target	 interaction	can	also	 induce	translational	 repression	without	affecting	
the	mRNA	 stability	 by	 blocking	 translational	 initiation	 or	 elongation68.	 In	 addition	 to	 direct	 target	
suppression,	miRNAs	can	indirectly	regulate	gene	expression	owing	to	the	competition	of	transcripts	
sharing	 the	 same	 miRNA	 binding	 sites,	 termed	 competing	 endogenous	 RNAs82.	 Therefore,	 the	
suppression	 of	 one	 miRNA	 target	 may	 result	 in	 the	 upregulation	 of	 other	 targets	 of	 the	 same	
miRNA82.	
	
Figure	5:	Dicer-mediated	processing	of	pre-miRNAs	 in	 the	cytoplasm.	Dicer	cleaves	 the	pre-miRNA	near	 the	
terminal	 loop,	 thereby	 generating	 a	 miRNA	 duplex.	 The	 miRNA	 duplex	 is	 loaded	 onto	 Argonaute	 proteins.	
Following	 duplex	 unwinding,	 the	 guide	 strand	 (mature	 miRNA)	 remains	 bound	 to	 the	 Argonaute	 protein,	





More	 than	 60	 %	 of	 human	 protein-coding	 genes	 are	 predicted	 to	 be	 conserved	 miRNA	 targets,	
indicating	 the	 enormous	 regulatory	 potential	 of	 miRNAs83,84.	 One	 miRNA	 can	 theoretically	 target	
several	mRNAs	and	conversely,	one	mRNA	can	be	regulated	by	multiple	miRNAs,	thus	constituting	a	
complex	gene	regulatory	network	with	up	to	18,500	miRNA-mRNA	interactions	in	on	cell	type84,85.	In	
general,	 miRNAs	 can	 act	 as	 off-switches	 or	 fine-tuners	 of	 gene	 expression,	 thereby	 conferring	

















cell	 types.	 In	 adult	 mice,	 somatic	 Dicer	 deletion	 results	 in	 abnormalities	 of	 intestine	 and	 bone	
marrow,	 combined	 with	 a	 substantial	 reduction	 of	 the	 survival	 rate90.	 Deficiency	 of	 Dicer	 in	
pancreatic	 beta	 cells	 causes	 diabetes	 in	mice,	whereas	Dicer	 deletion	 in	 cardiomyocytes	 results	 in	
severe	hypertrophic	heart	 failure91,92.	Notably,	only	a	 small	 fraction	of	miRNAs	was	downregulated	
and	even	some	miRNAs	were	upregulated	in	the	heart	following	Dicer	deletion92.		
Whereas	deficiency	of	Dicer	 in	SMCs	causes	embryonic	 lethality	due	 to	 internal	hemorrhage,	EC-
specific	 Dicer	 deletion	 does	 not	 affect	 the	 development	 of	 mice	 or	 induce	 an	 overt	 phenotype,	
indicating	that	permanent	miRNA	biogenesis	is	of	less	importance	in	EC	than	in	SMC	homeostasis93-95.	
However,	 knock-out	 of	 endothelial	 Dicer	 severely	 impairs	 angiogenesis,	 resulting	 in	 diminished	 EC	
proliferation	and	migration93,96,97.	 In	vitro,	 knock-down	of	Dicer	 in	ECs	diminishes	 the	expression	of	
only	 a	 subset	 of	 miRNAs,	 probably	 owing	 to	 differences	 in	 the	 stability	 between	 miRNAs80,97.	
Moreover,	silencing	of	endothelial	Dicer	reduces	the	expression	of	CXCL1,	promotes	the	expression	
of	endothelial	nitric	oxide	synthase	(eNOS)	and	increases	nitric	oxide	(NO)	production,	indicating	that	







profile	 in	 ECs	 differs	 between	 atheroprone	 and	 atherosusceptible	 arterial	 regions	 characterized	by	
downregulation	 of	 atheroprotective	 miRNAs	 such	 as	 miR-10a	 and	 upregulation	 of	 proatherogenic	
miRNAs	such	as	miR-92a	or	miR-103	in	atheroprone	regions99.	Hyperlipidemia	further	 increases	the	
disturbed	flow-induced	expression	of	miR-92a,	indicating	that	hyperlipidemia	and	disturbed	flow	can	
have	 additive	 effects	 on	 miRNA	 expression100,101.	 MiR-92a	 induces	 NF-κB-dependent	 chemokine	
expression	and	monocyte	adhesion	most	 likely	by	suppressing	KLF2	and	KLF4	 in	ECs,	both	of	which	
inhibit	NF-κB	activation	(Figure	6)100.	 In	addition,	miR-712	promotes	endothelial	NF-κB	activation	by	
inducing	 tumor	necrosis	 factor-α	 (TNF-α)	 release	 from	the	endothelium	(Figure	6)102.	 In	contrast	 to	
miR-92a	 and	miR-712,	miR-181b	 and	miR-10a	 inhibit	 NF-κB	 activation	 in	 ECs	 by	 impairing	 nuclear	
translocation	of	NF-κB,	thereby	contributing	to	an	anti-inflammatory	EC	phenotype	(Figure	6)99,103,104.	
In	 particular,	 miR-181b,	 which	 is	 downregulated	 by	 hyperlipidemia	 and	 TNF-α,	 reduces	 the	
expression	 of	 inflammatory	 chemokines	 such	 as	 CXCL1	 and	 C-X3-C	motif	 chemokine	 1	 (CX3CL1)	 in	
TNF-α-stimulated	ECs103,104.	To	resolve	prolonged	EC	inflammation,	NF-κB-induced	miR-146a	negative	
feedbacks	 to	 NF-κB	 by	 stabilizing	 the	 KLF2	 mRNA	 (Figure	 6)105.	 By	 regulating	 EC	 inflammation,	
miRNAs	might	contribute	to	the	formation	of	atherosclerotic	lesions.	For	instance,	systemic	inhibition	
of	 miR-92a	 or	 overexpression	 of	 miR-181b	 in	 mice	 reduces	 atherosclerosis	 by	 limiting	 NF-κB	
activation;	 these	 effects	 are	 most	 likely	 attributed	 to	 reduced	 EC	 inflammation100,104.	 Although	






endothelial	 miRNAs	 is	 incompletely	 understood.	 The	 transcription	 factor	 HIF-1α	 can	 regulate	 the	
expression	of	miRNAs,	thus	termed	hypoxia-responsive	miRNAs106.	For	 instance,	HIF-1α	induces	the	
expression	of	miR-107,	which	promotes	VEGF-mediated	 angiogenesis	 during	hypoxia106.	Moreover,	
HIF-1α	 and	miR-429	 constitute	 in	 a	 negative	 feedback	 loop	 that	 limits	 VEGF	 expression	 in	 ECs107.	
During	 atherosclerosis	 the	 expression	 of	 HIF-1α	 is	 associated	 with	 lesion	 progression	 and	 lesional	
inflammation108,109.	Endothelial	HIF-1α	and	NF-κB	reciprocally	amplify	each	other,	thereby	regulating	
EC	 function26.	However,	 it	 is	 unclear	whether	HIF-1α-regulated	miRNAs	are	 involved	 in	 the	mutual	
activation	of	HIF-1α	and	NF-κB	in	infammatory	ECs	during	atherosclerosis.		
	
Figure	 6:	 MiRNAs	 control	 the	 inflammatory	 activation	 in	 ECs.	 Individual	 miRNAs	 control	 NF-κB-mediated	
endothelial	 inflammation	 in	 response	 to	 atherogenic	 stimuli,	 such	 as	 disturbed	 flow.	 Disturbed	 flow	
upregulates	the	expression	of	miR-92a	and	miR-712	in	ECs.	MiR-92a	promotes	NF-κB	activation	by	suppressing	
KLF4/2	 expression	 and	miR-712	 induces	 the	 release	 of	 soluble	 TNF-α	 from	 the	 endothelium.	 In	 turn,	 TNF-α	
represses	 the	expression	of	miR-181b	 in	 the	endothelium,	which	 limits	 the	nuclear	 translocation	of	NF-κB	by	
targeting	 importin	 α3	 (IPOA3).	Moreover,	 NF-κB	 promotes	miR-146a	 expression,	 which	 restrains	 endothelial	
inflammation.	Disturbed	flow	promotes	the	proatherogenic	phenotype	in	ECs	by	suppressing	miR-10a	that	acts	
as	 a	 negative	 regulator	 of	 NF-κB10.	 Abbreviations:	 miR,	 microRNA;	 NF-κB,	 nuclear	 factor-κB;	 TNF-α,	 Tumor-












targeting	negative	 feedback	mediators,	such	as	B-cell	 lymphoma	6	 (BCL6),	Src	homology	2	domain-
containing	 inositol-5-phosphatase	 (SHIP-1)	 and	 suppressor	 of	 cytokine	 signaling	 1	 (SOCS1)	
(Figure	7)110,112,114,115.	Suppression	of	BCL6	by	miR-155	 induces	NF-κB-dependent	expression	of	CCL2	
and	 TNF-α	 in	macrophages,	 thereby	 promoting	 atherosclerosis110.	Moreover,	miR-155	 induces	 the	
expression	 of	 miR-147	 in	 macrophages,	 indicating	 that	 miRNAs	 can	 regulate	 their	 expression	
reciprocally116.	 MiR-155	 plays	 a	 crucial	 role	 in	 macrophages	 during	 atherosclerosis;	 however,	 the	
function	 of	 miR-342-5p,	 which	 is	 also	 upregulated	 during	 atherosclerosis,	 in	 the	 formation	 of	




Figure	 7:	MiR-155	 regulates	macrophage	 inflammation	during	 atherosclerosis.	 YY1	 and	AKT1	downregulate	
the	 expression	 of	 miR-155,	 whereas	 oxLDL	 upregulates	 the	 expression	 of	 miR-155.	 MiR-155	 promotes	
macrophage	 inflammation	 through	 the	 inhibition	 of	 several	 negative	 regulators,	 such	 as	 BCL6,	 SHIP-1	 and	
SOCS110.	Abbreviations:	AKT1,	thymoma	viral	proto-oncogene	1;	BCL6,	B-cell	 lymphoma	6;	miRNA,	microRNA;	










Inflammatory	 activation	 of	 ECs	 triggers	 the	 adhesion	 of	 monocytes	 at	 arterial	 bifurcations.	
Endothelial	miRNAs	have	been	 implicated	 in	endothelial	 inflammation	during	atherosclerosis.	Dicer	
processes	almost	all	mature	miRNAs	and	promotes	the	expression	of	proinflammatory	genes	in	ECs	
in	vitro.	Although	individual	miRNAs	affect	endothelial	 inflammation,	the	role	of	Dicer	in	ECs	during	
atherosclerosis	 is	 unclear.	 We	 hypothesized	 that	 endothelial	 Dicer	 affects	 the	 inflammatory	
activation	of	ECs	during	atherosclerosis	by	processing	miRNAs.	
Therefore,	we	investigated	the	role	of	endothelial	Dicer	on	monocyte	adhesion	and	atherosclerosis.	
We	 studied	 the	 effect	 of	 endothelial	 Dicer	 deletion	 on	 miRNA	 expression	 in	 the	 arteries	 of	
atherosclerotic	mice.	We	investigated	whether	the	effects	of	endothelial	Dicer	on	EC	function	during	




HIF-1α	 is	 expressed	 in	 atherosclerotic	 lesions	 and	 correlates	 with	 inflammation	 during	
atherosclerosis.	 In	 ECs,	 HIF-1α	 and	 NF-κB	 activate	 each	 other	 through	 a	 positive	 feedback	 loop.	
However,	 the	 exact	 mechanism	 of	 the	 interaction	 between	 HIF-1α	 and	 NF-κB	 is	 incompletely	
understood.	In	addition	to	the	transcriptional	regulation	of	protein-coding	genes,	HIF-1α	mediates	its	
effects	 through	 the	 regulation	of	miRNAs.	We	hypothesized	 that	endothelial	HIF-1α	plays	a	 role	 in	
atherosclerosis	by	regulating	miRNAs,	which	induce	NF-κB	activation.		






response.	 Upregulated	 miRNAs	 during	 atherosclerosis,	 such	 as	 miR-155,	 play	 a	 crucial	 role	 in	
atherosclerosis.	In	addition	to	miR-155,	miRNA	expression	profiles	identified	a	selective	upregulation	











Endothelial	 Dicer	 promotes	 atherosclerosis	 and	 vascular	 inflammation	 by	 miRNA-103-mediated	
suppression	of	KLF4	
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The	 microRNA-342-5p	 Fosters	 Inflammatory	 Macrophage	 Activation	 Through	 an	 Akt1-	 and	
microRNA-155–Dependent	Pathway	During	Atherosclerosis	















































































































































































































































































































Chemokine-mediated	 monocyte	 adhesion	 to	 inflammatory	 ECs	 results	 in	 subendothelial	
accumulation	 of	 macrophages	 and	 initiates	 the	 formation	 of	 atherosclerotic	 lesions.	 The	







atherosclerosis	 using	 Tamoxifen-inducible	 Cadherin5-CreERT2Dicerflox/floxapolipoprotein	 E-/-	 (Apoe-/-)	
mice	fed	a	high-cholesterol	diet.	Deletion	of	endothelial	Dicer	in	Apoe-/-	mice	diminished	endothelial	
chemokine	 expression,	 monocyte	 adhesion	 to	 atherosclerosis-prone	 endothelium,	 lesional	
macrophage	accumulation	and	reduced	atherosclerotic	 lesion	formation	compared	to	control	mice.	
MiRNA	 expression	 profiles	 in	 atherosclerotic	 arteries	 of	Apoe-/-	mice	 showed	 that	Dicer	deficiency	
lowers	 the	 expression	 levels	 of	 miR-103,	 -433,	 -301b	 and	 -652,	 most	 of	 which	 were	 upregulated	
during	 atherosclerosis	 progression.	 Among	 those	 downregulated	 miRNAs,	 miR-103	 was	 most	
abundantly	expressed	in	human	aortic	ECs	(HAECs)	and	enriched	in	the	RISC	of	ECs.	Accordingly,	ECs	
covering	mouse	and	human	atherosclerotic	lesions	expressed	miR-103.	Stimulation	with	moxLDL	and	
activation	 of	 NF-κB	 by	 TNF-α	 upregulated	 the	 expression	 of	 miR-103	 in	 HAECs.	 Gain-and-loss-of-
function	 studies	 showed	 that	miR-103	 promotes	 the	 expression	 of	 the	 chemokines	CXCL1,	 CX3CL1	
and	CCL2	in	HAECs.	Moreover,	overexpression	of	miR-103	in	HAECs	increased	monocyte	adhesion	to	
ECs,	 which	 was	 reversed	 by	 blocking	 the	 CXCL1-receptor	 C-X-C	 chemokine	 receptor	 type	 2	 on	
monocytes.	Genome-wide	microarray	analysis	of	atherosclerotic	arteries	 from	Apoe-/-	mice	showed	
that	 endothelial	 Dicer	 deletion	 induces	 the	 differential	 expression	 of	 genes	 related	 to	 the	 Klf4	
pathway,	 indicating	 increased	 Klf4	 signaling.	Dicer	 deficiency	 increased	 Klf4	 protein	 expression	 in	
atherosclerotic	 endothelium	 in	mice.	Moreover,	KLF4	was	enriched	 in	 the	RISC	of	HAECs	 in	 a	miR-
103-dependent	manner	and	miR-103	inhibition	increased	KLF4	protein	levels,	indicating	that	KLF4	is	a	
target	 of	 miR-103	 in	 ECs.	 Inhibition	 of	 the	 interaction	 between	miR-103	 and	 KLF4	 via	 the	 known	
binding	 site	 in	 the	KLF4	 3`	 UTR	 using	 target	 site	 blocker	 oligonucleotides	 (KLF4-TSBs)	 reduced	 the	
expression	 of	 CXCL1,	 CX3CL1	 and	 CCL2	 and	 monocyte	 adhesion	 to	 HAECs.	 Systemic	 treatment	 of	
Apoe-/-	 mice	 with	 KLF4-TSBs	 significantly	 reduced	 lesional	 macrophage	 accumulation,	 lesion	
formation	and	endothelial	Cxcl1	expression,	showing	a	proinflammatory	and	proatherogenic	role	of	
miR-103	by	targeting	KLF4.			
Taken	 together,	 Dicer	 promotes	 endothelial	 inflammation	 and	 atherosclerosis,	 at	 least	 partly	
through	miR-103-mediated	 suppression	 of	 KLF4.	MiR-103	might	 act	 as	 a	molecular	 switch	 for	 the	
inflammatory	activation	of	arterial	ECs	by	 fine-tuning	the	 functional	antagonism	between	KLF4	and	







The	 transcription	 factor	 HIF-1α	 is	 expressed	 in	 various	 cell	 types	 of	 atherosclerotic	 lesions	 and	 its	
expression	correlates	with	 lesional	 inflammation	and	atherosclerotic	 lesion	progression.	Endothelial	
NF-κB	 and	 HIF-1α	 amplify	 each	 other	 through	 a	 positive	 feedback	 loop,	 thereby	 regulating	 EC	
functions.	 In	addition	to	 the	transcriptional	 regulation	of	protein-coding	genes,	HIF-1α	mediates	 its	
effects	by	 the	regulation	of	 several	miRNAs	 in	ECs.	However,	 it	 is	unknown	whether	HIF-1α	affects	
endothelial	inflammation	during	atherosclerosis	by	regulating	miRNAs.		
Hyperlipidemia	 increased	the	expression	and	activation	of	Hif-1α	 in	aortic	ECs	of	Apoe-/-	mice.	To	
study	 the	 role	 of	 endothelial	 HIF-1α	 in	 atherosclerosis,	 we	 used	 Apoe-/-	 mice	 that	 express	 a	
Tamoxifen-inducible	 Cre-recombinase	 (CreERT2)	 under	 the	 control	 of	 the	 EC-specific	 Cadherin5	
promoter	 after	 feeding	 a	 high-cholesterol	 diet.	 Deletion	 of	 endothelial	 Hif1a	 reduced	 Cxcl1	
expression,	 the	 lesional	 macrophage	 content	 and	 lesion	 formation,	 compared	 to	 control	 mice.	
Moreover,	 computed	 tomographic	 angiography	 showed	 that	 the	 luminal	 volume	 is	 significantly	





carotid	arteries	of	Apoe-/-	mice	 showed	 that	deficiency	of	endothelial	Hif1a	 selectively	 reduces	 the	
expression	 of	 miR-19a	 in	 ECs.	 HIF-1α	 induced	 the	 expression	 of	 miR-19a	 in	 moxLDL-stimulated	
HAECs.	 Gain-and-loss-of-function	 studies	 showed	 that	 miR-19a	 promotes	 the	 expression	 of	 the	
chemokines	 CXCL1	 and	 CCL2	 in	 moxLDL-stimulated	 HAECs.	 Moreover,	 miR-19a	 triggered	 NF-κB	
activation	and	enhanced	CXCL1-mediated	monocyte	adhesion	to	HAECs.		
In	conclusion,	enhanced	HIF-1α	activation	in	atherosclerotic	ECs	promotes	the	expression	of	CXCL1	
and	 increases	 atherosclerosis.	 The	proatherogenic	 effect	of	 endothelial	HIF-1α	might	be	due	 to	 an	
increased	 expression	 of	miR-19a,	which	 triggers	 NF-κB	 activation	 and	 CXCL1-dependent	monocyte	




Macrophages	 promote	 atherosclerosis	 by	 driving	 an	 unresolved	 inflammation	 in	 atherosclerotic	
lesions.	 Upregulated	 miRNAs	 during	 atherosclerosis,	 such	 as	 miR-155,	 play	 a	 crucial	 role	 in	
atherosclerosis.	 For	 instance	 miR-155	 promotes	 the	 NF-κB-mediated	 inflammatory	 activation	 of	
macrophages	 during	 atherosclerosis.	 In	 addition	 to	 miR-155,	 miRNA	 expression	 profiles	 identified	
that	miR-342-5p	is	selectively	upregulated	in	early	atherosclerotic	lesions.	The	aim	of	the	study	is	to	
investigate	the	so	far	unknown	role	of	miR-342-5p	in	atherosclerosis.		
MiR-342-5p	was	 specifically	 expressed	 in	 lesional	macrophages	 and	 suppressed	 the	 kinase	Akt1,	
which	is	known	to	negatively	regulate	the	expression	of	miR-155.	MiR-342-5p-mediated	suppression	
of	Akt1	induced	Nos2	and	Il6	expression	in	macrophages	via	the	upregulation	of	miR-155.	Inhibition	
of	 miR-342-5p	 in	 atherosclerotic	 Apoe-/-	 mice	 by	 systemic	 injection	 of	 antisense	 oligonucleotides	


















von	 Monozyten,	 die	 sich	 dort	 in	 Makrophagen	 differenzieren.	 Die	 entzündliche	 Aktivierung	 von	




Dicer	 ist	 für	 die	 Prozessierung	 von	 nahezu	 allen	 miRNAs	 und	 für	 die	 Expression	 von	
entzündungsfördernden	 Genen	 in	 Endothelzellen	 verantwortlich.	 Die	 Rolle	 von	 Dicer	 in	 der	
entzündlichen	Aktivierung	von	Endothelzellen	während	der	Atherosklerose	ist	jedoch	nicht	bekannt.	
Das	 Ziel	 der	 vorliegenden	 Arbeit	 ist	 es,	 den	 Effekt	 eines	 endothelialen	 Dicer	 Knock-outs	 auf	 die	
Atherosklerose	 zu	 untersuchen.	 Dafür	 wurden	 Tamoxifen-induzierbare	 Cadherin5-
CreERT2Dicerflox/flox/apolipoprotein	E-/-	 (Apoe-/-)-Mäuse	mit	einer	cholesterinreichen	Diät	gefüttert.	 Im	
Vergleich	zu	den	Kontrollmäusen,	verminderte	die	endotheliale	Dicer-Deletion	in	Apoe-/--Mäusen	die	
Expression	 endothelialer	 Chemokine,	 die	 Adhäsion	 von	 Monozyten	 an	 Endothelzellen,	 die	
Anreicherung	 von	Makrophagen	 in	 der	 Gefäßwand	 sowie	 die	 Ausbildung	 von	 atherosklerotischen	
Plaques.	 MiRNA-Expressionsanalysen	 in	 atherosklerotischen	 Arterien	 von	 Apoe-/--Mäusen	 zeigten,	
dass	die	Deletion	des	endothelialen	Dicer-Gens	vor	allem	die	Expression	der	miRNAs	miR-103,	-433,	-
301b	und	-652	vermindert.	Der	Großteil	dieser	miRNAs	zeigte	eine	erhöhte	Expression	während	der	
Atherosklerose.	 Unter	 diesen	 vier	 miRNAs	 war	 miR-103	 am	 stärksten	 in	 humanen	 aortalen	
Endothelzellen	 (HAECs)	 exprimiert	 als	 auch	 am	 stärksten	 im	RISC	 von	 Endothelzellen	 angereichert.	
Ferner	 wurde	 miR-103	 in	 Endothelzellen	 aus	 humanen	 und	 murinen	 atherosklerotischen	 Plaques	
exprimiert.	Eine	Stimulation	mit	moxLDL	sowie	eine	TNF-α-induzierte	Aktivierung	von	NF-κB	steigerte	
die	miR-103-Expression	in	HAECs.	„Gain-and-loss-of-function“-Experimente	zeigten,	dass	miR-103	die	
Expression	 der	 Chemokine	 CXCL1,	 CX3CL1	 und	 CCL2	 in	 HAECs	 erhöht.	 Ferner	 induzierte	 eine	
Überexpression	 von	 miR-103	 in	 HAECs	 eine	 gesteigerte	 Monozytenadhäsion	 an	 Endothelzellen,	
welche	 durch	 die	 Inhibition	 des	 CXCL1-Rezeptors	 C-X-C-Chemokine	Rezeptor	 Typ	 2	 auf	Monozyten	
gehemmt	werden	konnte.	Eine	genomweite	Genexpressionsanalyse	 in	atherosklerotischen	Arterien	
von	 Apoe-/--Mäusen	 zeigte,	 dass	 das	 Fehlen	 von	 endothelialem	 Dicer	 eine	 differenzielle	
Genregulation	 von	 vorwiegend	 KLF4-regulierten	 Genen	 induziert.	 Dies	 wies	 auf	 eine	 gesteigerte	
Aktivierung	 des	 Klf4-Signalweges	 in	 diesen	 Mäusen	 hin.	 Zudem	 erhöhte	 der	 endotheliale	 Dicer-
Knock-out	 in	 Apoe-/--Mäusen	 die	 Klf4-Proteinexpression	 in	 atherosklerotischen	 Endothelzellen.	
Darüber	 hinaus	 reicherte	 sich	 KLF4	 in	 Abhängigkeit	 von	 miR-103	 im	 RISC	 von	 HAECs	 an	 und	 die	
Inhibition	 von	 miR-103	 führte	 zu	 einer	 erhöhten	 KLF4-Proteinexpression	 in	 diesen	 Zellen.	 Diese	
Ergebnisse	 lassen	 darauf	 schließen,	 dass	 KLF4	 ein	 Target	 von	 miR-103	 ist.	 Das	 Blockieren	 der	
Interaktion	 von	 miR-103	 und	 KLF4	 über	 die	 bekannte	 miR-103-Bindungsstelle	 in	 der	 KLF4	 3`	 UTR	
mittels	spezifischer	„Target	Site	Blocker“-Oligonukleotide	 (KLF4-TSBs)	 reduzierte	die	Expression	von	
CXCL1,	CX3CL1	und	CCL2	sowie	die	Monozytenadhäsion	an	HAECs.	Eine	systemische	Behandlung	von	
Apoe-/--Mäusen	mit	 KLF4-TSBs	 reduzierte	 den	Makrophagenanteil	 in	 den	 Plaques,	 verminderte	 die	
Ausbildung	 von	 atherosklerotischen	 Plaques	 sowie	 die	 endotheliale	 Cxcl1-Expression.	 Diese	





Zusammenfassend	 zeigen	 diese	 Daten,	 dass	 Dicer	 die	 endotheliale	 Entzündung	 sowie	 die	
Atherosklerose	fördert.	Dieser	Effekt	ist	zumindest	teilweise	auf	die	miR-103-vermittelte	Suppression	
von	KLF4	zurückzuführen.	Durch	das	Regulieren	des	funktionellen	Antagonismus	zwischen	KLF4	und	






Der	 Transkriptionsfaktor	 HIF-1α	 wird	 in	 verschiedenen	 Zelltypen	 atherosklerotischer	 Plaques	
exprimiert.	Die	Expression	von	HIF-1α	korreliert	mit	der	Entzündungsaktivität	in	atherosklerotischen	
Plaques	 sowie	 mit	 der	 Progression	 der	 Atherosklerose.	 NF-κB	 und	 HIF-1α	 steigern	 durch	 einen	
positiven	 Feedback-Mechanismus	 ihre	 Expression	 in	 Endothelzellen	 wechselseitig	 und	 regulieren	




Eine	 Hyperlipidämie	 induzierte	 die	 Expression	 und	 Aktivierung	 von	 Hif-1α	 in	 aortalen	
Endothelzellen	von	Apoe-/--Mäusen.	Um	die	Rolle	von	endothelialem	HIF-1α	in	der	Atherosklerose	zu	
untersuchen,	 wurden	 Apoe-/--Mäuse,	 welche	 eine	 Tamoxifen-induzierbare	 Cre-Rekombinase	
(CreERT2)	 unter	 der	 Kontrolle	 des	 Endothel-spezifischen	 Cadherin5	 Promoters	 exprimieren,	 nach	
Gabe	 einer	 cholesterinreichen	 Diät	 verwendet.	 Im	 Vergleich	 zu	 Kontrollmäusen,	 reduzierte	 die	




durch	 moxLDL	 oder	 dessen	 Derivat	 LPA	 20:4-induzierte	 endotheliale	 Cxcl1-Expression	 und	
Monozytenadhäsion	 wurde	 durch	 die	 gesteigerte	 Hif-1α-Expression	 vermittelt.	 Das	 Blockieren	 der	
LPA-Rezeptoren	 reduzierte	 die	 moxLDL-induzierte	 Cxcl1	 und	Hif1a-Expression	 in	 murinen	 aortalen	
Endothelzellen.	 Diese	 Ergebnisse	 deuten	 darauf	 hin,	 dass	 moxLDL	 mittels	 ungesättigten	 LPAs	 die	
Expression	 von	 HIF-1α	 steigert	 und	 dadurch	 die	 CXCL1-vermittelte	 Monozytenadhäsion	 induziert.	
MiRNA-Expressionsanalysen	aus	atherosklerotischen	Karotiden	von	Apoe-/--Mäusen	zeigten,	dass	das	
Fehlen	 von	endothelialem	Hif1a	 die	 Expression	 von	miR-19a	 in	 Endothelzellen	 selektiv	 vermindert.	
HIF-1α	 induzierte	 die	 Expression	 von	 miR-19a	 in	 moxLDL-stimulierten	 HAECs.	 „Gain-and-loss-of-
function“-Experimente	 zeigten,	 dass	 miR-19a	 die	 Expression	 der	 Chemokine	 CXCL1	 und	 CCL2	 in	
moxLDL-stimulierten	HAECs	 steigert.	 Ferner	 steigerte	miR-19a	die	Aktivierung	von	NF-κB	 sowie	die	
CXCL1-vermittelte	Monozytenadhäsion	an	HAECs.			
Zusammenfassend	 zeigen	 diese	 Ergebnisse,	 dass	 eine	 gesteigerte	 HIF-1α-Aktivierung	 in	










Die	 chronische	 Entzündung	 in	 atherosklerotischen	 Plaques	 wird	 durch	 die	 Dysfunktion	 von	
Makrophagen	 gefördert.	 MiRNAs,	 die	 während	 der	 Atherosklerose	 hochreguliert	 werden,	 spielen	
eine	 wichtige	 Rolle	 in	 der	 Atherosklerose.	 Zum	 Beispiel	 induziert	 miR-155	 im	 Rahmen	 der	




In	 atherosklerotischen	 Plaques	 von	 Apoe-/--Mäusen	 war	 miR-342-5p	 vor	 allem	 in	 Makrophagen	
exprimiert.	MiR-342-5p	supprimierte	die	Expression	der	Kinase	Akt1,	von	welcher	bekannt	 ist,	dass	
sie	die	Expression	von	miR-155	inhibiert.	Die	Suppression	von	Akt1	durch	miR-342-5p	induzierte	die	
Expression	 von	Nos2	 und	 Il6	 in	 inflammatorischen	Makrophagen	 vermittelt	 durch	 eine	 gesteigerte	
Expression	 von	 miR-155.	 Das	 Blockieren	 der	 miR-342-5p	 mittels	 systemischer	 Injektion	 von	
Antisense-Oligonukleotiden	 reduzierte	 die	 Plaqueprogression	 und	 die	 Akt1-vermittelte	 Nos2-
Expression	 in	 Makrophagen	 in	 atherosklerotischen	 Apoe-/--Mäusen.	 Einhergehend	 mit	 der	
reduzierten	 Nos2-Expression	 in	 Makrophagen,	 führte	 die	 Hemmung	 von	 miR-342-5p	 zu	 einer	
verminderten	 Bildung	 von	 Nitrotyrosin	 und	 somit	 zu	 einem	 verminderten	 nitrosativen	 Stress	 in	
atherosklerotischen	Plaques.		








The	maladaption	of	 ECs	 to	 disturbed	 flow	at	 atherosusceptible	 arterial	 bifurcations	 primes	 ECs	 for	
inflammatory	activation	in	response	to	hyperlipidemic	stress.	The	findings	of	the	current	study	show	
that	 Dicer	 generates	 endothelial	 miRNAs,	 like	 miR-103,	 which	 promote	 atherosclerotic	 lesion	
formation	 by	 increasing	 endothelial	 inflammation.	 Thus,	 Dicer	 might	 be	 a	 crucial	 regulator	 of	
endothelial	 maladaption.	 These	 findings	 may	 represent	 a	 novel	 concept	 in	 the	 regulation	 of	
endothelial	inflammation	based	on	endothelial	miRNAs.		
Moreover,	 the	 findings	of	 the	 study	 indicate	 that	 the	half-life	of	miRNAs	 in	ECs	differs	greatly.	A	
subset	 of	 endothelial	 miRNAs,	 including	 miR-103,	 appears	 to	 have	 a	 low	 stability	 during	
atherosclerosis	and	their	expression	is	highly	dependent	on	permanent	Dicer	activity.	This	could	be	
due	 to	 a	 high	 turnover	 rate	 of	 miR-103	 in	 ECs,	 which	 might	 be	 related	 to	 its	 disease	 specific	
expression	 and	 minor	 role	 in	 cell	 homeostasis.	 It	 will	 be	 necessary	 to	 further	 investigate	 the	
regulation	and	function	of	miRNA	stability	in	ECs	to	gain	more	insights	into	its	role	in	EC	homeostasis.		
Inhibition	of	miRNAs	using	antisense	oligonucleotides	 is	a	potential	 therapeutic	 tool	and	 the	 first	
anti-miRNA-based	 drug	 was	 successfully	 tested	 in	 a	 phase	 2a	 human	 clinical	 trial117.	 However,	
miRNA-specific	 antisense-oligonucleotides	 result	 in	 the	 derepression	 of	 multiple	 miRNA	 targets,	
which	may	cause	unwanted	side	effects.	In	contrast,	inhibition	of	one	miRNA-mRNA	interaction	using	
TSBs	 could	 increase	 the	 specificity	 of	 the	 therapeutic	 effect	 by	 preventing	 the	 inhibition	 of	 other	
miRNA-mRNA	 interactions.	 In	 this	 study,	we	 tested	 for	 the	 first	 time	 the	 effect	 of	 TSBs	 in	 vivo	 on	
atherosclerosis.	 Selective	 inhibition	 of	 the	 interaction	 between	 miR-103	 and	 KLF4	 reduced	
atherosclerosis	 and	 endothelial	 inflammation	 in	 the	 arteries	 of	 atherosclerotic	 mice	 due	 to	 the	
upregulation	of	KLF4.	These	novel	miRNA-targeting	 inhibitors	that	block	the	 interaction	of	a	miRNA	
with	a	specific	target,	seem	to	be	highly	specific	and	may	therefore	represent	in	general	a	promising	
new	 approach	 for	 anti-miRNA-based	 therapeutic	 strategies	 and	 a	 promising	 strategy	 to	 treat	
atherosclerosis.		
Moreover,	the	findings	of	the	study	provide	further	insights	into	the	mutual	activation	of	NF-κB	and	
HIF-1α	 in	 ECs.	 HIF-1α-mediated	 upregulation	 of	miR-19a	 promotes	 NF-κB	 activation,	 which	 can	 in	
turn	 positively	 feedback	 to	 HIF-1α,	 thereby	 promoting	 EC	 inflammation.	 MiR-19a	 might	 induce	
endothelial	 NF-κB	 activation	 by	 inhibiting	 a	 negative	 regulator	 of	 NF-κB118.	 Thus,	 miR-19a	
posttranscriptionally	controls	NF-κB	activation,	which	might	be	more	responsive	to	cellular	changes	
than	transcriptional	controls,	thereby	representing	a	rapid	and	transient	regulation	of	the	NF-κB	and	
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